Accord Healthcare Limited – Trademark Portfolio
Entity Type: 99
Accord Healthcare Limited holds 7 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 7 filings in this category. The portfolio also extends into Class 10 (Medical Apparatus) across 3 Nice Classification classes. Currently, 6 trademarks are registered. Notable registered marks include JUBEREQ, OSVYRTI, ANSKUELY, IMULDOSA, and ACCORD ANIMAL HEALTH.
Sage House, 319 Pinner Road
Harrow, Middlesex HA1 4HF
Showing of trademarks Trademarks
Trademark Classifications
Accord Healthcare Limited's trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Medical services; veterinary services; hygienic and beauty care for human beings or animals
Frequently Asked Questions
How many trademarks does Accord Healthcare Limited have?
Accord Healthcare Limited has 7 U.S. trademarks filed with the USPTO. Of these, 6 registered, 1 cancelled.
What trademark classes does Accord Healthcare Limited file in?
Accord Healthcare Limited files trademarks across 3 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus), Class 44 (Medical Services). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are Accord Healthcare Limited's most well-known trademarks?
Accord Healthcare Limited's registered trademark portfolio includes well-known marks such as JUBEREQ, OSVYRTI, ANSKUELY, IMULDOSA, and ACCORD ANIMAL HEALTH. These are among 6 currently registered trademarks in the portfolio.
What is Accord Healthcare Limited's trademark registration success rate?
Accord Healthcare Limited has a 86% trademark registration rate, with 6 out of 7 resolved applications resulting in successful registration. Currently, 0 applications are pending review.